| Primary |
| Product Used For Unknown Indication |
32.2% |
| Fungal Infection |
9.4% |
| Sepsis |
8.2% |
| Candidiasis |
5.8% |
| Drug Use For Unknown Indication |
5.0% |
| Systemic Candida |
5.0% |
| Candida Infection |
4.8% |
| Pneumonia |
4.3% |
| Prophylaxis |
3.8% |
| Antifungal Prophylaxis |
3.1% |
| Aspergillus Infection |
2.6% |
| Aspergillosis |
2.4% |
| Septic Shock |
2.4% |
| Infection |
1.9% |
| Oesophageal Candidiasis |
1.9% |
| Pancreatitis Acute |
1.7% |
| Acute Myeloid Leukaemia |
1.4% |
| Antifungal Treatment |
1.4% |
| Device Related Infection |
1.2% |
| Pyrexia |
1.2% |
|
| Off Label Use |
54.9% |
| Death |
18.3% |
| Septic Shock |
3.2% |
| No Adverse Event |
2.8% |
| Candidiasis |
2.1% |
| Drug Ineffective |
2.1% |
| Sepsis |
2.1% |
| Vomiting |
1.8% |
| Drug Resistance |
1.4% |
| Liver Disorder |
1.4% |
| Pyrexia |
1.4% |
| Hypersensitivity |
1.1% |
| Multi-organ Failure |
1.1% |
| Overdose |
1.1% |
| Renal Failure |
1.1% |
| Respiratory Failure |
1.1% |
| Systemic Candida |
1.1% |
| Accidental Exposure To Product |
0.7% |
| Agranulocytosis |
0.7% |
| Aspergillosis |
0.7% |
|
| Secondary |
| Product Used For Unknown Indication |
19.2% |
| Prophylaxis |
10.5% |
| Sepsis |
7.7% |
| Antibiotic Prophylaxis |
7.0% |
| Aspergillosis |
5.2% |
| Peritoneal Abscess |
5.2% |
| Antifungal Prophylaxis |
4.5% |
| Bacteraemia |
4.2% |
| Systemic Candida |
3.8% |
| Graft Versus Host Disease |
3.5% |
| Hypokalaemia |
3.1% |
| Liver Transplant |
3.1% |
| Sedation |
3.1% |
| Complications Of Transplant Surgery |
2.8% |
| Dyspepsia |
2.8% |
| Embolism Venous |
2.8% |
| Fungal Infection |
2.8% |
| Lung Disorder |
2.8% |
| Myoclonus |
2.8% |
| Streptococcal Infection |
2.8% |
|
| Off Label Use |
53.1% |
| Death |
7.3% |
| Multi-organ Failure |
4.2% |
| Device Related Infection |
3.1% |
| Fistula |
3.1% |
| Rash Generalised |
3.1% |
| Transplant Dysfunction |
3.1% |
| Blood Urea Increased |
2.1% |
| Candidiasis |
2.1% |
| Cardiac Arrest |
2.1% |
| Drug Resistance |
2.1% |
| Nephropathy Toxic |
2.1% |
| Overdose |
2.1% |
| Pyrexia |
2.1% |
| Respiratory Failure |
2.1% |
| Systemic Candida |
2.1% |
| Blood Bilirubin Abnormal |
1.0% |
| Chills |
1.0% |
| Cholestasis |
1.0% |
| Drug Ineffective |
1.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
55.6% |
| Multiple Myeloma |
6.4% |
| Prophylaxis |
5.5% |
| Pain |
3.9% |
| Anxiety |
2.9% |
| Full Blood Count Decreased |
2.9% |
| Acute Myeloid Leukaemia |
2.3% |
| Myelodysplastic Syndrome |
2.3% |
| Acute Myeloid Leukaemia Recurrent |
1.9% |
| Atrial Fibrillation |
1.9% |
| Bone Marrow Conditioning Regimen |
1.9% |
| Crohn's Disease |
1.9% |
| Drug Use For Unknown Indication |
1.6% |
| Nausea |
1.6% |
| Epistaxis |
1.3% |
| Glioblastoma |
1.3% |
| Hypertension |
1.3% |
| Plasma Cell Myeloma |
1.3% |
| Transfusion |
1.3% |
| Aplastic Anaemia |
1.0% |
|
| Thrombocytopenia |
18.2% |
| Pneumonia |
12.1% |
| 5Q Minus Syndrome |
9.1% |
| Pancreatitis Acute |
9.1% |
| Upper Respiratory Tract Infection |
6.1% |
| Acute Respiratory Failure |
3.0% |
| Anaemia |
3.0% |
| Cardiac Failure Congestive |
3.0% |
| Convulsion |
3.0% |
| Cytolytic Hepatitis |
3.0% |
| Death |
3.0% |
| Device Related Sepsis |
3.0% |
| Enterococcal Bacteraemia |
3.0% |
| Fungal Sepsis |
3.0% |
| Hepatotoxicity |
3.0% |
| Hypertension |
3.0% |
| Hypoxia |
3.0% |
| Ischaemic Cardiomyopathy |
3.0% |
| Muscle Spasms |
3.0% |
| Nephropathy Toxic |
3.0% |
|
| Interacting |
| Antibiotic Therapy |
50.0% |
| Atrial Fibrillation |
50.0% |
|
| Cytolytic Hepatitis |
50.0% |
| Drug Interaction |
50.0% |
|
